Important Safety Information Prescribing Information Print This Page
Sign up for updates



You are about to leave CAVERJECT.com

This Web site requested is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services on this site.

Click to Continue
Back to Previous Page

Additional Resources

Additional Resources are right at your fingertips

Want to learn more about erectile dysfunction? Click on any of the links listed below. They are full of helpful information.

WebMD*

American Urological Association Foundation*

1000 Corporate Boulevard
Linthicum, MD 21090
1-866-RING-AUA (1-866-746-4282)

National Kidney and Urologic Diseases Information Clearinghouse*

3 Information Way
Bethesda, MD 20892-3580
1-800-891-5390

* When you select any of the links above, you will be leaving CAVERJECT.com and going to a site that is not controlled by and not in a network with Pfizer Inc.

Pfizer Inc. is neither affiliated with nor endorse any of the above organizations. The information provided by Pfizer Inc., or these organizations is meant for informational purposes only and does not replace your doctor’s medical advice. So be sure to follow up with your healthcare provider regarding your options.



CAVERJECT is used to treat erectile dysfunction (ED) due to neurogenic, vasculogenic, psychogenic, or mixed etiology.


Important Safety Information

CAVERJECT should not be used in men hypersensitive to alprostadil, men with conditions that may predispose them to priapism (such as sickle cell anemia or trait, multiple myeloma or leukemia), men with anatomical deformities of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), men with penile implants, or men for whom sexual activity is inadvisable or is contraindicated.

CAVERJECT should not be used in women, children or newborns.

Patients should be instructed to immediately report to his physician any erection lasting 4 hours or longer. If unavailable, patient must seek immediate medical assistance.

CAVERJECT can cause penile fibrosis or Peyronie’s disease.

Use of Caverject in patients who take anticoagulants, such as warfarin or heparin, should be with precaution as they may have increased tendency for bleeding after Caverject injections.

The most common side effect of CAVERJECT® (alprostadil for injection) was penile pain, reported by 37% of patients in clinical studies. Other side effects were prolonged erection, penile fibrosis and injection site hematoma. To lower the risk of prolonged erections or priapism, Caverject should be titrated slowly to the lowest effective dose.

For Full Prescribing Information for CAVERJECT®, including Instructions for Use, please click here.